Published in Hepatitis Weekly, January 19th, 2004
Sheldon Fenton, chief executive officer, said, "The company has positioned its patented products to substantially increase revenue opportunities in tandem with national and multi-national distributors.
The hepatitis kill claims should increase demand for Veridien's infection control products in multiple markets."
Veridien's Antiseptic Products are effective tools for healthcare professionals...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.